A
AXOLABS GMBH
Axolabs is the leading custom research organization providing high-end preclincal solutions and consultancy in the field of oligonucleotide therapeutics and nucleic acid medicines. Our expert team has 18+ years of experience in the field of oligonucleotide therapeutics and has access to an excellent infrastructure. As the company is part of the LGC Group our customers also benefit from the multiple resources and expertise right across LGC.
Country/Area ：Germany
Company Email ：hr@axolabs.com
Industry ：Business ServicesBusiness Services GeneralElectrical/Electronic Manufacturing
Company address ：FRITZ HORNSCHUCH STR DE
Company website ：*****
Company phone ：+49 9221827620
Established ：2007
Company Revenue ：$5,436,000
Number of employees ：11-50
SIC Code ：87873
NAICS Code ：54541
Web Summary
Q1: What is the address of Axolabs GmbH?
A1: The text does not explicitly mention the current address of Axolabs GmbH, but it mentions that Axolabs has a pilot & large-scale cGMP manufacturing site in Berlin, Germany.
Q2: What products or services does Axolabs offer?
A2: Axolabs is a CRDMO (Contract Research and Manufacturing Organization) that offers various services including CRO (Contract Research Organization), CDMO (Contract Development and Manufacturing Organization), and resources for the development of nucleic acid therapeutics.
Q3: In which industry is Axolabs primarily involved?
A3: Axolabs is primarily involved in the pharmaceutical and biotechnology industries, specifically in the development and manufacturing of RNA and oligonucleotide-based therapeutics.
Q4: What is the contact information for Axolabs?
A4: The text does not provide a direct phone number or email address for Axolabs. However, it mentions that Laurent Alexandre joined LGC in February 2025 as Vice President, Head of Global Commercial CDMO for Axolabs, suggesting that one can contact them through their parent company.
Q5: Who are the key leaders at Axolabs?
A5: The key leaders at Axolabs include Dr. Alexander Zahiri (Executive Vice President and General Manager), Dr. Philipp Hadwiger (Vice President, Head of Research & Development), Dr. Ingo Röhl (Vice President, Head of Operations CRO), Peter Rose (Vice President, Head of Operations CDMO), and Laurent Alexandre (Vice President, Head of Business Development).
Q6: What is the history of Axolabs?
A6: Axolabs was established through a management buy-out of assets from Roche Kulmbach GmbH in 2007. The company has since grown and expanded its operations, including the acquisition by LGC Group in 2011.
Q7: Where are Axolabs' facilities located?
A7: Axolabs has facilities in Berlin, Germany, where they have established a pilot & large-scale cGMP manufacturing site for oligonucleotide production.
Q8: What is the significance of Axolabs' expansion in 2025?
A8: In 2025, Axolabs expanded its operations with the establishment of a new GMP-certified manufacturing facility in Berlin, Germany, marking a significant milestone in the company's growth and commitment to nucleic acid therapeutics development.
A1: The text does not explicitly mention the current address of Axolabs GmbH, but it mentions that Axolabs has a pilot & large-scale cGMP manufacturing site in Berlin, Germany.
Q2: What products or services does Axolabs offer?
A2: Axolabs is a CRDMO (Contract Research and Manufacturing Organization) that offers various services including CRO (Contract Research Organization), CDMO (Contract Development and Manufacturing Organization), and resources for the development of nucleic acid therapeutics.
Q3: In which industry is Axolabs primarily involved?
A3: Axolabs is primarily involved in the pharmaceutical and biotechnology industries, specifically in the development and manufacturing of RNA and oligonucleotide-based therapeutics.
Q4: What is the contact information for Axolabs?
A4: The text does not provide a direct phone number or email address for Axolabs. However, it mentions that Laurent Alexandre joined LGC in February 2025 as Vice President, Head of Global Commercial CDMO for Axolabs, suggesting that one can contact them through their parent company.
Q5: Who are the key leaders at Axolabs?
A5: The key leaders at Axolabs include Dr. Alexander Zahiri (Executive Vice President and General Manager), Dr. Philipp Hadwiger (Vice President, Head of Research & Development), Dr. Ingo Röhl (Vice President, Head of Operations CRO), Peter Rose (Vice President, Head of Operations CDMO), and Laurent Alexandre (Vice President, Head of Business Development).
Q6: What is the history of Axolabs?
A6: Axolabs was established through a management buy-out of assets from Roche Kulmbach GmbH in 2007. The company has since grown and expanded its operations, including the acquisition by LGC Group in 2011.
Q7: Where are Axolabs' facilities located?
A7: Axolabs has facilities in Berlin, Germany, where they have established a pilot & large-scale cGMP manufacturing site for oligonucleotide production.
Q8: What is the significance of Axolabs' expansion in 2025?
A8: In 2025, Axolabs expanded its operations with the establishment of a new GMP-certified manufacturing facility in Berlin, Germany, marking a significant milestone in the company's growth and commitment to nucleic acid therapeutics development.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
